The Herschel Multi‐tiered Extragalactic Survey (HerMES) is a legacy programme designed to map a set of nested fields totalling ∼380 deg2. Fields range in size from 0.01 to ∼20 deg2, using the Herschel‐Spectral and Photometric Imaging Receiver (SPIRE) (at 250, 350 and 500 μm) and the Herschel‐Photodetector Array Camera and Spectrometer (PACS) (at 100 and 160 μm), with an additional wider component of 270 deg2 with SPIRE alone. These bands cover the peak of the redshifted thermal spectral energy distribution from interstellar dust and thus capture the reprocessed optical and ultraviolet radiation from star formation that has been absorbed by dust, and are critical for forming a complete multiwavelength understanding of galaxy formation and evolution. The survey will detect of the order of 100 000 galaxies at 5σ in some of the best‐studied fields in the sky. Additionally, HerMES is closely coordinated with the PACS Evolutionary Probe survey. Making maximum use of the full spectrum of ancillary data, from radio to X‐ray wavelengths, it is designed to facilitate redshift determination, rapidly identify unusual objects and understand the relationships between thermal emission from dust and other processes. Scientific questions HerMES will be used to answer include the total infrared emission of galaxies, the evolution of the luminosity function, the clustering properties of dusty galaxies and the properties of populations of galaxies which lie below the confusion limit through lensing and statistical techniques. This paper defines the survey observations and data products, outlines the primary scientific goals of the HerMES team, and reviews some of the early results.

Using Herschel data from the deepest SPIRE and PACS surveys (HerMES and PEP) in COSMOS, GOODS-S and GOODS-N, we examine the dust properties of infrared (IR)luminous (L IR > 10 10 L ) galaxies at 0.1 < z < 2 and determine how these evolve with cosmic time. The unique angle of this work is the rigorous analysis of survey selection effects, making this the first study of the star-formation-dominated, IR-luminous population within a framework almost entirely free of selection biases. We find that IR-luminous galaxies have spectral energy distributions (SEDs) with broad far-IR peaks characterized by cool/extended dust emission and average dust temperatures in the 25-45 K range. Hot (T > 45 K) SEDs and cold (T < 25 K), cirrus-dominated SEDs are rare, with most sources being within the range occupied by warm starbursts such as M82 and cool spirals such as M51. We observe a luminosity-temperature (L−T ) relation, where the average dust temperature of log [L IR /L ] ∼ 12.5 galaxies is about 10 K higher than that of their log [L IR /L ] ∼ 10.5 counterparts. However, although the increased dust heating in more luminous systems is the driving factor behind the L−T relation, the increase in dust mass and/or starburst size with luminosity plays a dominant role in shaping it. Our results show that the dust conditions in IR-luminous sources evolve with cosmic time: at high redshift, dust temperatures are on average up to 10 K lower than what is measured locally (z 0.1). This is manifested as a flattening of the L−T relation, suggesting that (ultra)luminous infrared galaxies [(U)LIRGs] in the early Universe are typically characterized by a more extended dust distribution and/or higher dust masses than local equivalent sources. Interestingly, the evolution in dust temperature is luminosity dependent, with the fraction of LIRGs with T < 35 K showing a two-fold increase from z ∼ 0 to z ∼ 2, whereas that of ULIRGs with T < 35 K shows a six-fold increase. Our results suggest a greater diversity in the IR-luminous population at high redshift, particularly for ULIRGs.

Airway smooth muscle is actively involved in the inflammatory process in diseases such as chronic obstructive pulmonary disease and asthma by 1) contributing to airway narrowing through hyperplasia and hypertrophy and 2) the release of GM-CSF and G-CSF, which promotes the survival and activation of infiltrating leukocytes. Thus, the identification of novel anti-inflammatory pathways in airway smooth muscle will have important implications for the treatment of inflammatory airway disease. This study identifies such a pathway in the activation of peroxisome proliferator-activated receptors (PPARs). PPAR ligands are known therapeutic agents in the treatment of diabetes; however, their role in human airway disease is unknown. We demonstrate, for the first time, that human airway smooth muscle cells express PPARα and -γ subtypes. Activation of PPARγ by natural and synthetic ligands inhibits serum-induced cell growth more effectively than does the steroid dexamethasone, and induces apoptosis. Moreover, PPARγ activation, like dexamethasone, inhibits the release of GM-CSF. However, PPARγ ligands, but not dexamethasone, similarly inhibits G-CSF release. These results reveal a novel anti-inflammatory pathway in human airway smooth muscle, where PPARγ activation has additional anti-inflammatory effects to those of steroids. Hence, PPAR ligands might act as potential treatments in human respiratory diseases.

We present the cross-identification and source photometry techniques used to process Herschel SPIRE imaging taken as part of the Herschel Multi-Tiered Extragalactic Survey (HerMES). Cross-identifications are performed in map-space so as to minimize source-blending effects. We make use of a combination of linear inversion and model selection techniques to produce reliable cross-identification catalogues based on Spitzer MIPS 24-??m source positions. Testing on simulations and real Herschel observations shows that this approach gives robust results for even the faintest sources (S250??? 10 mJy). We apply our new technique to HerMES SPIRE observations taken as part of the science demonstration phase of Herschel. For our real SPIRE observations, we show that, for bright unconfused sources, our flux density estimates are in good agreement with those produced via more traditional point source detection methods (SUSSEXtractor) by Smith et al. When compared to the measured number density of sources in the SPIRE bands, we show that our method allows the recovery of a larger fraction of faint sources than these traditional methods. However, this completeness is heavily dependent on the relative depth of the existing 24-??m catalogues and SPIRE imaging. Using our deepest multiwavelength data set in the GOODS-N, we estimate that the use of shallow 24-??m catalogues in our other fields introduces an incompleteness at faint levels of between 20???40 per cent at 250 ??m

1 There is considerable interest in novel therapies for cough, since currently used agents such as codeine have limited beneficial value due to the associated side effects. Sensory nerves in the airways mediate the cough reflex via activation of C-fibres and RARs. Evidence suggests that cannabinoids may inhibit sensory nerve-mediated responses. 2 We have investigated the inhibitory actions of cannabinoids on sensory nerve depolarisation mediated by capsaicin, hypertonic saline and PGE 2 on isolated guinea-pig and human vagus nerve preparations, and the cough reflex in conscious guinea-pigs. 3 The non-selective cannabinoid (CB) receptor agonist, CP 55940, and the selective CB 2 agonist, JWH 133 inhibited sensory nerve depolarisations of the guinea-pig vagus nerve induced by hypertonic saline, capsaicin and PGE 2 . These responses were abolished by the CB 2 receptor antagonist SR144528, and unaffected by the CB 1 antagonist SR141716A. Similarly, JWH 133 inhibited capsaicin-evoked nerve depolarisations in the human vagus nerve, and was prevented by SR144528. 4 Using a guinea-pig in vivo model of cough, JWH 133 (10 mg kg À1 , i.p., 20 min) significantly reduced citric acid-induced cough in conscious guinea pigs compared to those treated with the vehicle control. 5 These data show that activation of the CB 2 receptor subtype inhibits sensory nerve activation of guinea-pig and human vagus nerve, and the cough reflex in guinea-pigs, suggesting that the development of CB 2 agonists, devoid of CB 1 -mediated central effects, will provide a new and safe antitussive treatment for chronic cough.